IMS Health reports a 5.1 percent increase in U.S. prescription sales in 2009. Demand for prescription drugs (new therapies and refills) as well as new treatment options for cancer, thrombosis and atrial fibrillation, and new generic treatment options drove growth in the year immediately preceding. Top therapy areas in 2009 include antipsychotics, lipid regulators, proton pump inhibitors, antidepressants, and anti-neoplastic monoclonal antibodies.

Thought Leader Select is pleased to have helped companies strengthen relationships with key opinion leaders (KOLs) and clinical investigators in 40% of the major therapeutic areas driving industry growth in 2009. Thought Leader Select has identified, profiled, and provided engagement and deployment recommendations for more than 1000 KOLs in the areas of insulin analogs, anti-platelets, GI and inflammatory, seizure disorders, erythropoietins, and anti-arthritic/biologic response modifiers.

Read the full report here.